To evaluate the incidence and risk of nonscarring hair loss in adults treated with GLP-1 receptor agonists (RAs).
Key Findings:
At 6 months, GLP-1 RA use was associated with 1.62 times the odds of androgenetic alopecia (AGA) and 1.26 times the odds of overall nonscarring hair loss; however, the association with telogen effluvium (TE) did not reach statistical significance.
By 12 months, the odds increased to 1.76 for TE, 1.64 for AGA, and 1.40 for overall nonscarring hair loss.
Alopecia areata (AA) was not significantly associated with GLP-1 RA use and was more common among controls.
Interpretation:
The study suggests a significant association between GLP-1 RA use and increased risk of nonscarring hair loss, particularly AGA and TE, while AA appears unaffected. Proposed mechanisms include rapid weight loss, alterations in insulin signaling, androgen changes, and possible direct follicular effects.
Limitations:
Retrospective, database-driven design may introduce residual confounding; the small sample size in the pediatric subgroup limits analysis and impacts the reliability of findings.
Conclusion:
Awareness of alopecia risk in patients on GLP-1 RAs is critical for early detection and care; further research is needed on mechanisms and pediatric outcomes.
